INFLIXIMAB

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
Shaina Sekhri, Bharat Rao, Akanksha Mohananey, Poonam Beniwal-Patel, Alexandra Bruss, Daniel J Stein, Andres J Yarur

BMJ Open Gastroenterology Nov 2021, 8 (1) e000788; DOI: 10.1136/bmjgast-2021-000788
Successful use of TNFα blockade in a severe case of idiopathic non-granulomatous ulcerative jejunoileitis associated with thrombotic thrombocytopenic purpura
Fabian Braun, Victor Suarez, Johanna Dinter, Stefan Haneder, Alexander Quaas, Thomas Benzing, Dirk Nierhoff, Roman-Ulrich Müller

BMJ Open Gastroenterology Feb 2019, 6 (1) e000252; DOI: 10.1136/bmjgast-2018-000252
Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease
Ahmad Qasem, Seela Ramesh, Saleh A Naser

BMJ Open Gastroenterology Feb 2019, 6 (1) e000246; DOI: 10.1136/bmjgast-2018-000246
Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
M A Cozijnsen, M van Pieterson, J N Samsom, J C Escher, L de Ridder

BMJ Open Gastroenterology Dec 2016, 3 (1) e000123; DOI: 10.1136/bmjgast-2016-000123

Main menu